574 related articles for article (PubMed ID: 15702813)
41. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity.
Sánchez-Borges M; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2000 Jan; 84(1):101-6. PubMed ID: 10674573
[TBL] [Abstract][Full Text] [Related]
42. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
43. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
44. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
Quiralte J; Sáenz de San Pedro B; Florido JJ
Ann Allergy Asthma Immunol; 2002 Jul; 89(1):63-6. PubMed ID: 12141722
[TBL] [Abstract][Full Text] [Related]
45. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
46. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
[TBL] [Abstract][Full Text] [Related]
47. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Doña I; Blanca-López N; Jagemann LR; Torres MJ; Rondón C; Campo P; Gómez AI; Fernández J; Laguna JJ; Rosado A; Blanca M; Canto G
Allergy; 2011 Nov; 66(11):1428-33. PubMed ID: 21834936
[TBL] [Abstract][Full Text] [Related]
48. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
Pacor ML; Di Lorenzo G; Biasi D; Barbagallo M; Corrocher R
Clin Exp Allergy; 2002 Mar; 32(3):397-400. PubMed ID: 11940070
[TBL] [Abstract][Full Text] [Related]
49. Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS.
Trombetta D; Imbesi S; Vita G; Isola S; Minciullo PL; Saija A; Gangemi S
Arzneimittelforschung; 2009; 59(8):410-4. PubMed ID: 19813464
[TBL] [Abstract][Full Text] [Related]
50. Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Çelik GE; Erkekol FÖ; Aydın Ö; Demirel YS; Mısırlıgil Z
Allergol Immunopathol (Madr); 2013; 41(3):181-8. PubMed ID: 23031659
[TBL] [Abstract][Full Text] [Related]
51. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs.
Giuseppe P; Antonino R; Alessandro DB; Donato Q; Marina DF; Donatella P; Francesca G; Alberto V
Ann Allergy Asthma Immunol; 1997 Jan; 78(1):74-8. PubMed ID: 9012626
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
53. [Clinical pharmacology of the selective COX-2 inhibitors].
Burian M; Geisslinger G
Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
[TBL] [Abstract][Full Text] [Related]
54. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Di PR; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2002 Mar; 88(3):331-4. PubMed ID: 11926629
[TBL] [Abstract][Full Text] [Related]
55. Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema.
Nosbaum A; Braire-Bourrel M; Dubost R; Faudel A; Parat S; Nicolas JF; Bérard F
Ann Allergy Asthma Immunol; 2013 Apr; 110(4):263-6. PubMed ID: 23535090
[TBL] [Abstract][Full Text] [Related]
56. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Sánchez-Borges M; Capriles-Hulett A; Caballero-Fonseca F
Am J Clin Dermatol; 2002; 3(9):599-607. PubMed ID: 12444802
[TBL] [Abstract][Full Text] [Related]
57. Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs.
Asero R; Tedeschi A; Lorini M
Ann Allergy Asthma Immunol; 2002 May; 88(5):468-72. PubMed ID: 12027067
[TBL] [Abstract][Full Text] [Related]
58. Provocation tests with the offending nonsteroidal anti-inflammatory drugs in patients with urticaria/angioedema reactions.
Zisa G; Riccobono F; Bommarito L; D'Antonio C; Calamari AM; Poppa M; Moschella MA; Di Pietrantonj C; Galimberti M
Allergy Asthma Proc; 2012; 33(5):421-6. PubMed ID: 23026184
[TBL] [Abstract][Full Text] [Related]
59. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
[TBL] [Abstract][Full Text] [Related]
60. Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis.
Chaudhry T; Hissaria P; Wiese M; Heddle R; Kette F; Smith WB
Intern Med J; 2012 Jun; 42(6):665-71. PubMed ID: 21981353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
